Document Type
Article
Publication Date
11-15-2026
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the most treatment-resistant malignancies because of its dense desmoplastic stroma, metabolic plasticity, and immunosuppressive tumor microenvironment. Lactate, once viewed primarily as a glycolytic byproduct, also acts as an epigenetic signal through histone lactylation, particularly histone H3 lysine 18 lactylation (H3K18la). Recent PDAC studies implicate H3K18la in three distinct reported mechanisms: a glycolysis-H3K18la-TTK/BUB1B positive-feedback loop, an H3K18la-ACAT2-cholesterol axis that promotes macrophage-mediated immunosuppression, and a PCAF-H3K18la-CXCL1 pathway that recruits neutrophils and supports immune escape. Together, these findings identify the lactate-lactylation axis as a potential therapeutic vulnerability in PDAC. This review synthesizes evidence linking lactate metabolism, histone lactylation, immune remodeling, and therapeutic resistance, with emphasis on RNA-based interventions. We evaluate small interfering RNA, microRNA-based, antisense, and other non-coding RNA strategies directed at lactate production and transport, chromatin writers and erasers, and axis-specific effectors. We also examine translational barriers, including nuclease degradation, renal clearance, membrane impermeability, endosomal trapping, off-target effects, and limited penetration of nanoparticles through the PDAC stroma. Integrating cancer metabolism, epigenetics, immunology, and RNA nanomedicine, this review proposes a translational framework for testing lactylation-directed RNA therapeutics in PDAC.
Recommended Citation
Wakil MM, Sajid MI, Fatima F, Babar KN, Eshan M, Sohaib SN, Niskanen E, Chavez E, Tiwari RK and Parang K (2026) Targeting histone lactylation in pancreatic ductal adenocarcinoma using RNA therapeutics: from metabolic-epigenetic mechanisms to clinical translation. Front. Drug Discov. 6:2004992. https://doi.org/10.3389/fddsv.2026.2004992
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.
Included in
Cancer Biology Commons, Medical Immunology Commons, Medicinal and Pharmaceutical Chemistry Commons, Nucleic Acids, Nucleotides, and Nucleosides Commons, Oncology Commons, Therapeutics Commons
Comments
This article was originally published in Frontiers in Drug Discovery, volume 6, in 2026. https://doi.org/10.3389/fddsv.2026.2004992